<DOC>
	<DOCNO>NCT01835288</DOCNO>
	<brief_summary>This phase II trial study well arsenic trioxide work treat patient relapsed refractory acute myeloid leukemia . Drugs use chemotherapy , arsenic trioxide , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine complete remission rate relapse refractory acute myeloid leukemia ( AML ) patient Mutated Nucleophosmin 1 ( NPM1 ) gene . SECONDARY OBJECTIVES : I . Determine duration remission patient . II . Determine vivo biological effect arsenic trioxide AML mutate NPM1 . OUTLINE : Patients receive arsenic trioxide intravenously ( IV ) 1-2 hour daily 45 day . Patients achieve complete remission , receive arsenic trioxide IV 1-2 hour daily 5 day week 4 week . Treatment repeat every 8 week 4 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>AML , French American British ( FAB ) subtype except M3 , confirm mutation NPM1 gene Relapsed and/or refractory AML duration complete remission ( CR ) ; number prior therapy allow Eastern Cooperative Oncology Group ( ECOG ) performance status 02 , life expectancy &gt; 3 month Serum creatinine = &lt; 2.0 mg/dL Bilirubin = &lt; 2.0 mg/dL Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) = &lt; 3 x upper limit normal ( ULN ) Ability understand willingness sign write informed consent document Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event see animal/human study ; pregnancy test must obtain woman ; sexually active male female may participate unless agree use effective contraceptive method Patients currently receive another investigational drug Patients currently receive anticancer agent Uncontrolled systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) Known hypersensitivity arsenic trioxide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>